Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease

Core Insights - Quest Diagnostics has launched a novel blood test called Quest Flow Cytometry MRD for Myeloma, which offers sensitivity comparable to next-generation sequencing (NGS) methods for detecting measurable residual disease (MRD) in myeloma patients at a lower cost [1][4]. Company Overview - Quest Diagnostics is a leading provider of diagnostic information services, with a focus on oncology testing, including the new MRD test for myeloma and the Haystack MRD® test for solid tumors [6][8]. - The company operates approximately 7,000 phlebotomy sites across the United States, enhancing patient access to diagnostic testing [2]. Industry Context - Myeloma is a prevalent blood cancer with about 36,000 new cases diagnosed annually in the U.S., leading to nearly 11,000 deaths each year [3]. - The new test utilizes advanced flow cytometry techniques, providing a noninvasive alternative to traditional bone marrow aspirates, which is significant for patient care [4]. Test Features and Benefits - The Quest Flow Cytometry MRD for Myeloma test features five-day specimen stability, allowing for better logistics in specimen transport compared to conventional methods [4]. - The test is designed to be used even when a baseline aspirate sample is unavailable, unlike NGS methods that require such a reference [4]. Clinical Implications - The test is expected to improve treatment paradigms for myeloma patients and may serve as a response monitoring tool in clinical trials, aligning with recent FDA guidance on using MRD as a primary endpoint [5].